Researches

Displaying 171 - 180 of 4049
# Title Department Research Year
171 Design and synthesis of new 1, 2, 4-oxadiazole/quinazoline-4-one hybrids with antiproliferative activity as multitargeted inhibitors Department of Pharmaceutical Organic Chemistry 2024
172 Design and synthesis of New dihydropyrimidine/sulphonamide hybrids as promising anti-inflammatory agents via dual mPGES-1/5-LOX inhibition Department of Pharmaceutical Organic Chemistry 2024
173 Design and synthesis of novel quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases Department of Pharmaceutical Organic Chemistry 2024
174 Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives Department of Pharmaceutical Organic Chemistry 2024
175 Design, synthesis, and antiproliferative activity of new 1, 2, 3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAF V600E inhibitors Department of Pharmaceutical Organic Chemistry 2024
176 Design, synthesis, and antiproliferative activity of new indole/1,2,4-triazole/chalcone hybrids as EGFR and/or c-MET inhibitors Department of Pharmaceutical Organic Chemistry 2024
177 Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors Department of Pharmaceutical Organic Chemistry 2024
178 Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential antitumor agents Department of Pharmaceutical Organic Chemistry 2024
179 Design, synthesis, and molecular docking of novel 1,3, 4-triaryl pyrazole derivatives bearing methylsulfonyl moiety with anticancer activity through dual targeting CDK2 and COX-2 enzymes Department of Medicinal Chemistry 2024
180 Design, synthesis, biological evaluation and docking study of some new aryl and heteroaryl thiomannosides as FimH antagonists. Department of Pharmaceutical Organic Chemistry 2024